Virus-like particle vaccines and adjuvants: the HPV paradigm

作者: Franco Maria Buonaguro , Maria Lina Tornesello , Luigi Buonaguro

DOI: 10.1586/ERV.09.81

关键词:

摘要: Complex antigen structures currently represent the most-studied approach for prophylactic as well therapeutic vaccines. Different types of complex vaccines, including virus-like particles and virosomes, have been developed depending on nature viral pathogen they are trying to replicate (enveloped vs naked) or modality express antigenic epitopes (i.e., binding envelope protein liposomic structures). The structure these vaccines provides them with some adjuvanted properties, not uniformly present all particle types. further inclusion specific adjuvants in vaccine preparations can modify presentation such immune system a Th1 versus Th2 polarization efficacy. A paradigm relevance new immunological results obtained monophosphoryl lipid adjuvant formulation L1-based human papillomavirus-naked reduce cellul...

参考文章(213)
Harald Petry, Claudia Goldmann, Wolfgang Lüke, Oliver Ast, The use of virus-like particles for gene transfer. Current Opinion in Molecular Therapeutics. ,vol. 5, pp. 524- ,(2003)
Frederick R. Vogel, Michael F. Powell, A Compendium of Vaccine Adjuvants and Excipients Vaccine Design. ,vol. 6, pp. 141- 228 ,(1995) , 10.1007/978-1-4615-1823-5_7
D. Wadowska, Frederick S. B. Kibenge, E. Nagy, B. Qian, J. R. Cleghorn, Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells. Canadian Journal of Veterinary Research-revue Canadienne De Recherche Veterinaire. ,vol. 63, pp. 49- 55 ,(1999)
L Montross, S Watkins, R B Moreland, H Mamon, D L Caspar, R L Garcea, Nuclear assembly of polyomavirus capsids in insect cells expressing the major capsid protein VP1. Journal of Virology. ,vol. 65, pp. 4991- 4998 ,(1991) , 10.1128/JVI.65.9.4991-4998.1991
S GIANNINI, E HANON, P MORIS, M VANMECHELEN, S MOREL, F DESSY, M FOURNEAU, B COLAU, J SUZICH, G LOSONKSY, Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only Vaccine. ,vol. 24, pp. 5937- 5949 ,(2006) , 10.1016/J.VACCINE.2006.06.005
Qizhi Yao, Vinh Vuong, Min Li, Richard W. Compans, Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity Vaccine. ,vol. 20, pp. 2537- 2545 ,(2002) , 10.1016/S0264-410X(02)00160-3
Jörg Vollmer, Risini Weeratna, Paul Payette, Marion Jurk, Christian Schetter, Meike Laucht, Tanja Wader, Sibylle Tluk, Ming Liu, Heather L. Davis, Arthur M. Krieg, Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities European Journal of Immunology. ,vol. 34, pp. 251- 262 ,(2004) , 10.1002/EJI.200324032
Laura A. Koutsky, Kevin A. Ault, Cosette M. Wheeler, Darron R. Brown, Eliav Barr, Frances B. Alvarez, Lisa M. Chiacchierini, Kathrin U. Jansen, A controlled trial of a human papillomavirus type 16 vaccine. The New England Journal of Medicine. ,vol. 347, pp. 1645- 1651 ,(2002) , 10.1056/NEJMOA020586
H. H. Alphs, R. Gambhira, B. Karanam, J. N. Roberts, S. Jagu, J. T. Schiller, W. Zeng, D. C. Jackson, R. B. S. Roden, Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 105, pp. 5850- 5855 ,(2008) , 10.1073/PNAS.0800868105